Navigation Links
Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook
Date:11/10/2009

NEW YORK, Nov. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

The Global Drug Delivery Market: Research Trends and Market Outlook

http://www.reportlinker.com/p0158356/The-Global-Drug-Delivery-Market-Research-Trends-and-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

The Global Drug Delivery Market: Research Trends and Market Outlook is an up-to-date guide that assesses the current state of the drug delivery industry and its application to both the pharmaceutical and biotech industries. While the sector is still dominated by oral technologies, drug delivery systems have expanded to include more novel devices such as needleless injectables, PEGylation platforms and microelectromechanical devices. These technological advances extend the duration of a drug's action, increase delivery to target sites, reduce delivery to unwanted sites, and maximize drug absorption.

The expanding market for biotechnology and gene-based products, which by their very nature are difficult to administer, represents an emerging opportunity for drug delivery technologies. These technologies are first expected to come to market as reformulations of existing macromolecular therapies, such as insulin. This report analyzes the markets for oral, inhalable, injectable, transmucosal, transdermal and niche drug delivery technologies as they apply to both biotech and traditional pharmacological compounds.

Key Features of This Report:

  • A thorough overview of both marketed and emerging drug delivery technologies set to impact the global pharmaceutical market
  • Analysis of the opportunities and threats to the global drug delivery industry
  • Profiles of drug delivery companies along with key financial figures and technology/product portfolios
  • Market analysis and outlook for the leading drug delivery technologies, including oral, injectable, inhalable, transdermal, transmucosal and niche technologies
  • Profiles of key emerging drug delivery technologies and profiles of leading companies, by type of technology

Who Should Buy This Report:

  • Companies interested in understanding the wider opportunities and challenges in the drug delivery industry
  • Pharma/biotech companies wishing to identify potential drug delivery partners
  • Companies with a need for an expansive overview of the drug delivery market and the R&D trends that are driving the industry forward.

Table of Contents

1 Introducing the Field of Drug Delivery

1.1 The Value of Drug Delivery Systems

1.2 Drug Delivery and Product Differentiation

1.3 Drug Delivery and Patent Extension

1.4 The Optimal Time for Reformulation

1.5 Optimizing R&D Returns Through Drug Delivery

1.6 Opportunities and Threats to the Drug Delivery Sector

1.6.1 Opportunities for Growth in the Drug Delivery Sector

1.6.2 Threats to Additional Growth in the Drug Delivery Sector

1.7 Business Models of Drug Delivery Companies

2 An Overview of Drug Delivery Technologies

2.1 Oral Drug Delivery

2.1.1 Controlled Release

2.1.2 Sustained Release

2.1.3 Chronomodulation

2.1.4 Rapid Dissolving and Taste-masking Tablets

2.1.5 Macromolecular Drug Delivery

2.2 Inhalable Drug Delivery

2.2.1 Nebulizers

2.2.2 Metered Dose Inhalers (MDIs)

2.2.3 Dry Powder Inhalers (DPIs)

2.2.4 Limitations of Pulmonary Delivery Systems for Systemic Delivery

2.2.5 Aqueous Systems

2.3 Injectable Drug Delivery

2.3.1 Sustained Release Injectable Systems

2.3.2 Liposomal Systems

2.3.3 Needleless Systems

2.4 Transmucosal Drug Delivery

2.4.1 Buccal Delivery

2.4.2 Nasal

2.4.3 Rectal

2.4.4 Vaginal

2.5 Transdermal Drug Delivery

2.5.1 Passive Formulations

2.5.2 Active Formulations

2.6 Niche Technologies

2.6.1 Topical Systems

2.6.2 Gene Delivery

2.6.3 Implantable Systems

2.6.4 Drug Delivery Microchips

2.6.5 Nanotechnology

3 Drug Delivery Market Analysis

3.1 Key Market Segments

3.1.1 Oral Drug Delivery

3.1.1.1 Sales of Products Utilizing Oral Drug Delivery Technology

3.1.1.2 Key Therapeutic Areas for Oral Drug Delivery

3.1.1.3 Key Oral Drug Delivery Products Impacting Global Market

3.1.1.4 The Outlook for Oral Drug Delivery Technology

3.1.2 Inhalable Drug Delivery

3.1.2.1 Sales of Products Utilizing Inhalable Drug Delivery

3.1.2.2 Key Therapeutic Areas for Inhalable Drug Delivery

3.1.2.3 Key Inhalable Drug Delivery Products Impacting Global Market

3.1.2.4 The Outlook for Inhalable Drug Delivery Technology

3.1.3 Injectable Drug Delivery

3.1.3.1 Sales of Products Utilizing Injectable Drug Delivery Technology

3.1.3.2 Key Therapeutic Areas for Injectable Drug Delivery

3.1.3.3 Key Injectable Drug Delivery Products Impacting Global Market

3.1.3.4 The Outlook for Injectable Drug Delivery Technology

3.1.4 Transmucosal Drug Delivery

3.1.4.1 Sales of Products Utilizing Transmucosal Drug Delivery Technology

3.1.4.2 Key Therapeutic Areas for Transmucosal Delivery

3.1.4.3 Key Transmucosal Drug Delivery Products Impacting Global Market

3.1.4.4 The Outlook for Transmucosal Drug Delivery Technology

3.1.5 Transdermal Drug Delivery

3.1.5.1 Sales of Products Utilizing Transdermal Drug Delivery Technology

3.1.5.2 Key Therapeutic Areas for Transdermal Drug Delivery

3.1.5.3 Key Transdermal Drug Delivery Products Impacting Global Market

3.1.5.4 The Outlook for Transdermal Drug Delivery Technology

3.1.6 Niche Drug Delivery Technologies

3.1.6.1 Sales of Products Utilizing Niche Drug Delivery Technologies

3.1.6.2 Key Niche Drug Delivery Technology Product Impacting Global Market

3.1.6.3 The Outlook for Niche Drug Delivery Technologies

4 Emerging Drug Delivery Technologies: Oral Drug Delivery

4.1 Key Product Profiles

4.2 Key Company Involvement in the Field of Oral Drug Delivery

4.2.1 ALZA

4.2.2 Biovail

4.2.3 Cardinal Health

4.2.4 Depomed

4.2.5 Emisphere

4.2.6 Ethypharm

4.2.7 Penwest

5 Emerging Drug Delivery Technologies: Inhalable Drug Delivery

5.1 Key Product Profiles

5.2 Key Company Involvement in the Field of Inhalable Drug Delivery

5.2.1 3M

5.2.2 Alkermes

5.2.3 Aradigm

5.2.4 Nektar

5.2.5 SkyePharma

6 Emerging Drug Delivery Technologies: Injectable Drug Delivery

6.1 Key Product Profiles

6.2 Key Company Involvement in the Field of Injectable Drug Delivery

6.2.1 Alkermes

6.2.2 ALZA

6.2.3 Aradigm

6.2.4 Enzon

6.2.5 Ethypharm

6.2.6 Macromed

6.2.7 Nektar

6.2.8 QLT

6.2.9 SkyePharma

7 Emerging Drug Delivery Technologies: Transmucosal Drug Delivery

7.1 Key Company Involvement in the Field of Transmucosal Drug Delivery

7.1.1 Generex

7.1.2 Nastech

7.1.3 Pherin

8 Emerging Drug Delivery Technologies: Transdermal Drug Delivery

8.1 Key Product Profiles

8.2 Key Company Involvement in the Field of Transdermal Drug Delivery

8.2.1 3M

8.2.2 Altea Therapeutics

8.2.3 ALZA

8.2.4 Noven

9 Emerging Drug Delivery Technologies: Niche Drug Delivery Technologies

9.1 Key Product Profiles

9.2 Key Company Involvement in Niche Drug Delivery Technologies

9.2.1 ALZA

9.2.2 Connetics

9.2.3 Inovio

9.2.4 MacroChem

9.2.5 NexMed

9.2.6 pSivida

9.2.7 QLT

9.2.8 SkyePharma

10 Key Drug Delivery Company Profiles

10.2 Alkermes

10.3 Altea Therapeutics

10.4 ALZA (Johnson & Johnson)

10.5 Aradigm

10.6 Bioject

10.7 Biovail

10.8 Cardinal Health

10.9 Cima Labs (Cephalon)

10.10 Connetics

10.11 CyDex

10.12 Delsite Biotechnologies (Carrington Laboratories)

10.13 Depomed

10.14 DOR BioPharma

10.15 DURECT

10.16 Emisphere

10.17 Enzon

10.18 Ethypharm

10.19 Generex

10.20 Inovio (formerly Genetronics)

10.21 IVAX

10.22 MacroChem

10.23 MacroMed

10.24 Nastech

10.25 Nektar

10.26 NexMed

10.27 Noven

10.28 Penwest

10.29 Pherin Pharmaceuticals

10.30 QLT

10.31 SkyePharma

10.32 Watson Pharmaceuticals

11 Leading Pharmaceutical Companies Utilizing Drug Delivery Technologies

11.1 Pfizer

11.2 GlaxoSmithKline

11.3 Sanofi-Aventis

11.4 Merck

11.5 Johnson & Johnson

11.6 AstraZeneca

11.7 Novartis

11.8 Bristol-Myers Squibb

11.9 Wyeth

11.10 Abbott Labs

List of Tables

Table 2.1 Drugs Suitable or Unsuitable for Controlled Release

Table 2.2 Advantages and Disadvantages of Transdermal Delivery

Table 2.3 Worldwide Government Funding for Nanotechnology R&D ($ mn)

Table 3.1 Key Oral Drug Delivery Products, 2004-2005 ($ mn)

Table 3.2 Leading Oral Drug Delivery Companies 2005, Key Products and Sales 2005 ($ mn)

Table 3.3 Key Inhalable Drug Delivery Products, 2004-2005 ($ mn)

Table 3.4 Key Injectable Drug Delivery Products, 2004-2005 ($ mn)

Table 3.5 Leading Injectable Drug Delivery Companies 2005, Key Products and Sales 2005 ($ mn)

Table 3.6 Key Transmucosal Drug Delivery Products, 2004-2005 ($ mn)

Table 3.7 Key Transdermal Drug Delivery Products, 2004-2005 ($ mn)

Table 3.8 Key Topical Drug Delivery Products, 2004-2005

Table 3.9 Key Niche Drug Delivery Products, 2004-2005 ($ mn)

Table 4.1 Key Oral Drug Delivery R&D Pipeline Drugs, 2006

Table 5.1 Key Inhalable Drug Delivery R&D Pipeline Drugs, 2006

Table 6.1 Key Injectable Drug Delivery R&D Pipeline Drugs, 2006

Table 6.2 SkyePharma's Injectables Pipeline

Table 7.1 Key Transmucosal Drug Delivery R&D Pipeline Drugs, 2006

Table 8.1 Key Transdermal Drug Delivery R&D Pipeline Drugs, 2006

Table 9.1 Key Topical Drug Delivery R&D Pipeline Drugs, 2006

Table 9.2 Key Niche Drug Delivery R&D Pipeline Drugs, 2006

Table 10.1 3M Key Financials, 2003-2005

Table 10.2 3M Drug Delivery Portfolio, 2006

Table 10.3 Alkermes Key Financials, 2003-2005

Table 10.4 Alkermes Drug Delivery Portfolio, 2006

Table 10.5 Altea Therapeutics Drug Delivery Portfolio, 2006

Table 10.6 ALZA Drug Delivery Portfolio, 2006

Table 10.7 Aradigm Key Financials, 2003-2005

Table 10.8 Aradigm Drug Delivery Portfolio, 2006

Table 10.9 Bioject Key Financials, 2003-2005

Table 10.10 Bioject Drug Delivery Portfolio, 2006

Table 10.11 Biovail Key Financials, 2003-2005

Table 10.12 Biovail Drug Delivery Portfolio, 2006

Table 10.13 Cardinal Health Key Financials, 2003-2005

Table 10.14 Cardinal Health Drug Delivery Portfolio, 2006

Table 10.15 Cephalon Key Financials, 2003-2005

Table 10.16 CIMA Labs Drug Delivery Portfolio, 2006

Table 10.17 Connetics Key Financials, 2003-2005

Table 10.18 Connetics Drug Delivery Portfolio, 2006

Table 10.19 CyDex Drug Delivery Pipeline, 2006

Table 10.20 Carrington Laboratories Key Financials, 2003-2005

Table 10.21 Depomed Key Financials, 2003-2005

Table 10.22 Depomed Drug Delivery Portfolio, 2006

Table 10.23 DOR BioPharma Key Financials, 2003-2005

Table 10.24 DOR BioPharma Drug Delivery Portfolio, 2006

Table 10.25 DURECT Key Financials, 2003-2005

Table 10.26 Durect Drug Delivery Portfolio, 2006

Table 10.27 Emisphere Key Financials, 2003-2005

Table 10.28 Emisphere Drug Delivery Portfolio, 2006

Table 10.29 Enzon Key Financials, 2003-2005

Table 10.30 Enzon Drug Delivery Portfolio, 2006

Table 10.31 Ethypharm Drug Delivery Portfolio, 2006

Table 10.32 Generex Key Financials, 2003-2005

Table 10.33 Generex Drug Delivery Portfolio, 2006

Table 10.34 Inovio Key Financials, 2003-2005

Table 10.35 Inovio Drug Delivery Portfolio, 2006

Table 10.36 IVAX Key Financials, 2003-2005

Table 10.37 IVAX Drug Delivery Portfolio, 2006

Table 10.38 MacroChem Key Financials, 2003-2005

Table 10.39 MacroChem Drug Delivery Portfolio, 2006

Table 10.40 MacroMed Drug Delivery Portfolio, 2006

Table 10.41 Nastech Key Financials, 2003-2005

Table 10.42 Nastech Drug Delivery Portfolio, 2006

Table 10.43 Nektar Key Financials, 2003-2005

Table 10.44 Nektar Drug Delivery Portfolio, 2006

Table 10.45 NexMed Key Financials, 2003-2005

Table 10.46 NexMed Drug Delivery Portfolio, 2006

Table 10.47 Noven Key Financials, 2003-2005

Table 10.48 Noven Drug Delivery Portfolio, 2006

Table 10.49 Penwest Key Financials, 2003-2005

Table 10.50 Penwest Drug Delivery Portfolio, 2006

Table 10.51 Pherin Pharmaceuticals Drug Delivery Portfolio, 2006

Table 10.52 QLT Key Financials, 2003-2005

Table 10.53 QLT Drug Delivery Portfolio, 2006

Table 10.54 SkyePharma Key Financials, 2003-2005

Table 10.55 SkyePharma Drug Delivery Portfolio, 2006

Table 10.56 Watson Pharmaceuticals Key Financials, 2003-2005

Table 10.57 Watson Pharmaceuticals Drug Delivery Portfolio, 2006

Table 11.1 Pfizer Key Financials, 2004-2005

Table 11.2 Pfizer Drug Delivery Portfolio, 2004-2005

Table 11.3 GlaxoSmithKline Key Financials, 2004-2005

Table 11.4 GlaxoSmithKline Drug Delivery Portfolio, 2004-2005

Table 11.5 Sanofi-Aventis Key Financials, 2004-2005

Table 11.6 Sanofi-Aventis Drug Delivery Portfolio, 2004-2005

Table 11.7 Merck Key Financials, 2004-2005

Table 11.8 Merck Drug Delivery Portfolio, 2004-2005

Table 11.9 Johnson & Johnson Key Financials, 2004-2005

Table 11.10 Johnson & Johnson Drug Delivery Portfolio, 2004-2005

Table 11.11 AstraZeneca Key Financials, 2004-2005

Table 11.12 AstraZeneca Drug Delivery Portfolio, 2004-2005

Table 11.13 Novartis Key Financials, 2004-2005

Table 11.14 Novartis Drug Delivery Portfolio, 2004-2005

Table 11.15 Bristol-Myers Squibb Key Financials, 2004-2005

Table 11.16 Bristol-Myers Squibb Drug Delivery Portfolio, 2004-2005

Table 11.17 Wyeth Key Financials, 2004-2005

Table 11.18 Wyeth Drug Delivery Portfolio, 2004-2005

Table 11.19 Abbott Labs Key Financials, 2004-2005

Table 11.20 Abbott Labs Drug Delivery Portfolio, 2004-2005

List of Graphs

Graph 3.1 Top 5 Products Utilizing Oral Delivery, Global Sales 2005 ($ mn)

Graph 3.2 Leading Oral Drug Delivery Companies, Combined Key Product Values 2005 ($ mn)

Graph 3.3 Key Therapeutic Areas of Emphasis for Oral Drug Delivery, # of Key Marketed Products

Graph 3.4 Top 5 Products Utilizing Inhalable Delivery, Global Sales 2005 ($ mn)

Graph 3.5 Inhalable Drug Delivery Market Share, by Technology 2005 ($ mn)

Graph 3.6 Top 5 Products Utilizing Injectable Delivery, Global Sales 2005 ($ mn)

Graph 3.7 Leading Injectable Drug Delivery Companies, Combined Key Product Values 2005 ($ mn)

Graph 3.8 Top 5 Products Utilizing Transmucosal Delivery, Global Sales 2005 ($ mn)

Graph 3.9 Leading Developers of Transmucosal-Based Therapeutics 2005 ($ mn)

Graph 3.10 Leading Transdermal Drug Delivery Companies, by # of Products on Market

Graph 3.11 Key Therapeutic Areas of Emphasis for Transdermal Drug Delivery, # of Key Marketed Products

Graph 4.1 Leading Companies Active in Oral Drug Delivery Development

Graph 4.2 Leading Indications for Oral Drug Delivery Products in Development

Graph 5.1 Leading Companies Active in Inhalable Drug Delivery Development

Graph 6.1 Leading Companies Active in Injectable Drug Delivery Development

Graph 7.1 Leading Companies Active in Injectable Drug Delivery Development

Graph 8.1 Leading Companies Active in Transdermal Drug Delivery Development

Graph 9.1 Leading Companies Active in Niche/Topical Drug Delivery Development

List of Figures

Figure 1.1 Optimal Time for Reformulation

Figure 1.2 Growth Prospects in the Drug Delivery Sector

Figure 6.1 Advanced PEGylated Drug Molecules

Figure 9.1 Connetics' VeraFoam Clinical Study Results

To order this report:

The Global Drug Delivery Market: Research Trends and Market Outlook

http://www.reportlinker.com/p0158356/The-Global-Drug-Delivery-Market-Research-Trends-and-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

    CONTACT:  Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):